empirical amiodarone in Japanese patients has not yet been clearly demonstrated. Therefore, the present study aims to evaluate the efficacy of empirical chronic oral amiodarone therapy in patients with sustained VT/VF and structural heart disease.
Methods

Patients
From 1989 to 1999, 207 patients with a history of symptomatic sustained VT/VF and structural heart disease were registered. Seventy-eight patients with a left ventricular ejection fraction (LVEF) of more than 0.50, or who had been given a treatment of radiofrequency catheter ablation or undergone surgery were excluded. Therefore, 129 patients with sustained VT/VF were studied, which comprised 50 patients with prior MI, 57 patients with dilated cardiomyopathy (DCM), and 22 patients with arrhythmogenic right ventricular dysplasia (ARVD).
Study Protocol
First, all 129 patients underwent an electrophysiological study (EPS) and a 24-h Holter electrocardiogram (ECG) recording to evaluate the efficacy of a class I anti-arrhythmic drug (disopyramide, procainamide, cibenzoline, mexiletine, aprindine, or propafenone), which had been selected empirically. After written informed consent was obtained, the EPS was performed while the patient was in a fasted, non-sedated state. The stimulation protocol consisted of The efficacy of empirical chronic oral amiodarone therapy in 129 patients with sustained ventricular tachyarrhythmia (VT/VF) and structural heart disease is evaluated. Twenty-nine patients were treated with class I drugs and monitored by electrophysiological study (EPS) and Holter electrocardiogram (ECG) (class I). The remaining 100 non-responders to the class I drugs were treated with oral amiodarone, of whom 70 were tolerant (AMD + ) and 30 were intolerant (AMD -). Patients were followed up to 36 months. The primary and secondary end-points were recurrence of VT/VF and hypothetical death, respectively; whereby, hypothetical death was defined as actual death and the event of rapid VT/VF (heart rate >240 beats/min) in patients with an implantable cardioverter defibrillator. Class I and AMD + patients showed a better prognosis than AMD -patients. The VT/VF event free at 36 months in class I (64.8%) and AMD + (56.1%) patients were significantly higher than that in AMD -(27.2%) (p<0.01) patients. Hypothetical survival rates in class I (92.0%) and AMD + (83.6%) patients were significantly higher than that in AMD -(57.0%) (p<0.001) patients, but there were no significant differences in the actual survival rate among the 3 patient groups. 9 which demonstrated a 70% reduction in the premature ventricular contraction count, an 80% reduction in the premature ventricular contraction pair count, a 90% reduction in the VT count, and an absence of any runs of VT longer than 15 beats. When the EPS results were not consistent with those from Holter monitoring, the EPS results were given preference.
A total of 29 patients who responded to a class I drug during EPS and/or Holter monitoring was continued on these drugs (class I group), and 100 patients who did not respond to the class I drugs were treated with amiodarone (loading dose at 300 or 400 mg/day for 2 weeks followed by a maintenance dose at 150 or 200 mg/day). Seventy patients continued treatment with amiodarone without any side-effects or recurrence of VT/VF at least 1 month after drug commencement (AMD + group). In the remaining 30 patients, amiodarone was discontinued because of either VT/VF recurrence or side-effects (AMD -group) (Fig 1) . Implantation of an ICD was recommended in those patients with one or more unsuccessful drug tests or in patients with a history of syncope as a result of VT/VF.
Follow-up
All patients in each group were followed for a maximum of 36 months. The primary end-point was the recurrence of VT/VF, and the secondary end-point was death from all causes. Hypothetical death was defined as actual total death plus the occurrence of rapid VT/VF (heart rate >240 beats/min) in patients with an ICD by assuming that a fast VT might be fatal.
Statistical Analysis
Continuous variables are expressed as the mean ± SD and compared by an unpaired t-test when appropriate. Multiple comparisons were made using one-way ANOVA, and individual data were compared using Scheffe's F test for factor analysis. Cumulative event rates were calculated by the Kaplan -Meier method; significance differences between treatment groups were assessed with the log-rank test; and Cox regression analysis was performed on patients' baseline characteristics to investigate and compare the influence of different variables. Statistical significance was established as p<0.05.
Results
Patients' Characteristics
The clinical characteristics of the 3 groups are shown in Table 1 . Age, gender, and underlying cause of heart disease did not differ between the groups. The LVEF value measured within 1 year before medication was significantly greater in the class I group than in the AMD + and AMDgroups (mean ± SD; 37±9 vs 31±11 and 30±9; p<0.05). Among the medical therapies, the frequency of -blocker usage was significantly higher in the class I group than in the AMD + and AMD -groups (76% vs 31% and 43%; p<0.05). Twenty patients (66%) in the AMD -group were not treated with any anti-arrhythmic drugs but received an ICD. The ratio of ICD implants was significantly higher in the AMD -and AMD + groups than in the class I group (80% and 30% vs 3%; p<0.01).
Follow up
The median duration of follow up was 21 months. Among the patients assigned to the AMD -group, the rate of VT/VF recurrence was 55.2% at 1 year and 72.8% at 3 years. Conversely, those in the class I group were 17.7% and 35.2%, and for the AMD + group were 24.3% and 43.9% at 1 and 3 years' follow up, respectively. The rate of VT/VF recurrence was significantly higher in the AMD -group compared with the class I and AMD + groups (p<0.01) (Fig 2) .
Among the patients assigned to the AMD -group, the hypothetical death rate was 35.4% at 1 year, and 43.0% at 3 years, and was 3.8% and 8.0% for the class I group, and 4.4% and 14.3% for the AMD + group, respectively. The hypothetical death rate was significantly higher for the AMD -group than for the class I or AMD + groups (p<0.001) (Fig 3A) . In contrast, the rate of actual death did not differ significantly among the 3 groups. The rates at 1 year were 3.8%, 4.4% and 21% for the class I, AMD + and AMDgroups, respectively, and the rates at 3 years were 8.0%, 14.3% and 25.4%, respectively (Fig 3B) . When the cycle length of VT recurrence was compared between the AMD + and AMD -groups, results showed that cycle length was prolonged significantly in the AMD + Fig 2. Recurrence of a ventricular tachycardia/fibrillation (VT/VF) event, unadjusted for the baseline characteristics. The recurrence rate of VT/VF was less in patients treated with class I anti-arrhythmic drugs (class I) and amiodarone (AMD + ) than in those patients treated without amiodarone (AMD -) (p<0.01). group (319±40 to 413±91 ms; p<0.001) but was not different in the AMD -group (306±36 to 318±66 ms; p=NS). The Cox hazard regression analysis results for VT/VF recurrence are shown in Table 2 , and indicate that the clinical factors age, gender, LVEF, and prior MI were unrelated to ventricular arrhythmia recurrence. With the exception of anti-arrhythmic drugs, the medication therapies were also unrelated to ventricular arrhythmia recurrence. The independent clinical factors that suppressed the recurrence of ventricular arrhythmias were found to be treatment with empirical amiodarone (p=0.019) and EPS/Holter-guided class I drugs (p=0.036), the odds ratio of which were 0.41 (95% confidence interval (CI), 0.19-0.86) and 0.37 (95% CI, 0.14-0.93), respectively.
Discussion
Major Findings
The present study demonstrated that VT/VF recurrence and hypothetical mortality were reduced significantly in patients who could tolerate chronic oral amiodarone therapy compared with those patients who could not. Even if administered empirically, those patients who could tolerate chronic amiodarone therapy had a good prognosis that was comparable to that of patients treated with EPS/Holterguided class I drugs. Thus, empirical amiodarone therapy may improve overall mortality, and also be a safe and easy strategy in high-risk patients with structural heart disease.
Long-Term Outcome of Amiodarone Therapy
Amiodarone has been used widely to control symptomatic ventricular arrhythmias, primarily in the prevention of VT/VF recurrence. [1] [2] [3] 10, 11 Although amiodarone is accepted as being an effective method of treatment against VT/VF, there is little supportive evidence for this from placebocontrolled studies. 12 Previous studies have reported that amiodarone reduces the risk of arrhythmic death or resuscitated VF, but have not demonstrated a significant reduction in overall mortality. [12] [13] [14] Meta-analyses of individual data from 13 randomized controlled clinical trials have suggested that amiodarone reduces the rate of arrhythmic/ sudden death in high-risk patients with recent MI or congestive heart failure, 15, 16 and that this effect results in an overall reduction of 13% in total mortality. [1] [2] [3] In these studies, MI was the underlying cause of heart disease in almost 80% of cases. Moreover, an evaluation of the antiarrhythmic effect of empirical amiodarone in patients with sustained VT/VF and non-ischemic cardiomyopathy has never been reported. In the present study, in more than half the patients studied the underlying cause of disease was non-ischemic cardiomyopathy, which includes DCM (44%) and ARVD (17%). Thus, this is the first study to evaluate empirical amiodarone in patients with symptomatic VT/VF with mainly non-ischemic cardiomyopathy.
Herre et al have reported that the recurrence rate of VT/VF after amiodarone therapy was 33% at 3 years, 10 and other studies have shown that the total mortality and arrhythmic event after amiodarone therapy was 10.9% and 4.0% per year, respectively. 3 In the present study, the VT/VF recurrence rate after amiodarone was 44% at 3 years, and the risk of hypothetical mortality and total mortality after amiodarone was 14% and 16%, respectively, at 3 years. Thus, more than 40% of patients have recurrent VT/VF at 3 years after receiving amiodarone. Nevertheless, the mortality rate improved to 16% because VT recurrence was rendered slower and more stable without any hemodynamic collapse, resulting in a reduction in the number of arrhythmic/sudden deaths.
Amiodarone and Class I Drugs
Class I anti-arrhythmic drugs might increase the mortality and arrhythmic deaths because of its pro-arrhythmic and negative inotropic effects. 17 The ESVEM trial, in which patients were treated with EPS or Holter-guided class I drugs, reported a poor prognosis due to a high recurrence rate of arrhythmias. 9 Another randomized trial has reported that empirical amiodarone therapy was more effective than EPS/Holter-guided class I therapy in high-risk survivors. 18 However, in the present study, patients treated with empirical amiodarone and EPS/Holter-guided class I drugs had almost the same prognosis, with a relatively low recurrence rate for either ventricular arrhythmias or mortality. The positive prognosis observed in the class I group might be because many of the patients had non-ischemic cardiomyopathy with a relatively good LVEF, and together with treatment with -blockers, was a beneficial combination.
Usefulness of Empirical Amiodarone Therapy
Grimm et al have reported that programmed ventricular stimulation is not helpful for evaluating arrhythmia risk stratification in patients with DCM, especially for those patients with an LVEF of less than 35%. 19 Results from the Multicenter Unsustained Tachycardia Trial (MUSTT) have suggested that EPS-guided anti-arrhythmic therapy without ICD therapy does not reduce the risk of sudden death in those patients with coronary artery disease and an LVEF of less than 40%. 5 These previous studies have suggested that EPS cannot be used to determine which anti-arrhythmic drugs are effective in patients with a lower LVEF.
In the present study, many of the patients who were given amiodarone therapy had a lower LVEF (mean ± SD, 31±11%). Therefore, even if it was used empirically, amiodarone therapy may have been an appropriate treatment for these patients with a lower LVEF. Moreover, the results of the present study are in agreement with those of a previous study which indicated that patients who responded to antiarrhythmic drug therapy had a better prognosis than those who did not. 20 Thus, the use of empirical amiodarone may improve overall mortality, and also be a safe and easy strategy in high-risk patients with structural heart disease.
Study Limitations
First, the study was not a prospective randomized study that evaluated the efficacy of amiodarone, therefore the directional efficacy of amiodarone in preventing the recurrence of VT/VF was not demonstrated but, instead, demonstrated an excellent prognosis for patients treated with oral amiodarone. Moreover, other drugs such as -blockers and angiotensin-converting enzyme inhibitors might have an effect; however, the Cox hazard regression analysis showed that drugs other than amiodarone were not significant factors in preventing the recurrence of VT/VF. Second, the study contained a small number of patients, and a multicenter trial with a large number of patients will be needed to demonstrate the effect of amiodarone therapy more accurately. Third, we defined the hypothetical death by assuming that fast VT/VF episodes (>240 beats/min) might be fatal; hence, the hypothetical survival rate for the AMDgroup might have been underestimated because some patients might have survived if their VT had terminated spontaneously.
Conclusion
Empirical amiodarone has a substantial long-term benefit that is comparable to EPS/Holter ECG-guided class I drugs in the treatment of high-risk patients with VT/VF and structural heart disease.
